Results 191 to 200 of about 24,603 (322)

Trustworthy navigation with variational policy in deep reinforcement learning. [PDF]

Front Robot AI
Bockrath K, Ernst L, Nadeem R, Pedraza B, Dera D.   +4 more
europepmc   +1 more source

Gradient Descent-based D-optimal Design for the Least-Squares Polynomial Approximation [PDF]

, 2018
Vitaly Zankin, Gleb Ryzhakov, Ivan Oseledets   +2 more
openalex   +1 more source

Crucial parameters for precise copy number variation detection in formalin‐fixed paraffin‐embedded solid cancer samples

Molecular Oncology, EarlyView.
This study shows that copy number variations (CNVs) can be reliably detected in formalin‐fixed paraffin‐embedded (FFPE) solid cancer samples using ultra‐low‐pass whole‐genome sequencing, provided that key (pre)‐analytical parameters are optimized.
Hanne Goris, Vasiliki Siozopoulou, Léon C van Kempen, Anne Sieben, Ella Roelant, Stig Hellemans, Elyne Backx, Laure Sorber, Koen De Winne, Senada Koljenović, Karen Zwaenepoel   +10 more
wiley   +1 more source

Auxin-induced depletion of human CCR4-NOT subunits reveals opposing functions of CNOT1 and CNOT4 in mRNA metabolism. [PDF]

J Biol Chem
Kulkarni S, Smith C, Akinniyi OT, Giardine BM, Keller CA, Arnaoutov A, Reese JC.   +6 more
europepmc   +1 more source

Redox regulation meets metabolism: targeting PRDX2 to prevent hepatocellular carcinoma

Molecular Oncology, EarlyView.
PRDX2 acts as a central redox hub linking metabolic dysfunction‐associated steatohepatitis (MASH) to hepatocellular carcinoma (HCC). In normal hepatocytes, PRDX2 maintains redox balance and metabolic homeostasis under oxidative stress. In contrast, during malignant transformation, PRDX2 promotes oncogenic signaling, stemness, and tumor initiation ...
Naroa Goikoetxea‐Usandizaga, María Luz Martinez‐Chantar, Carolina Conter   +2 more
wiley   +1 more source

Optimal Control in Combination Therapy for Heterogeneous Cell Populations with Drug Synergies. [PDF]

Bull Math Biol
Martina-Perez SF, Johnson SWS, Crossley RM, Kasemeier JC, Kulesa PM, Baker RE.   +5 more
europepmc   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Research on AGV based on improved A-star algorithm. [PDF]

Sci Rep
Guo Y, Tong X, Huang L, Deng K, Hu T, Ding J, Yang H, Zhong B.   +7 more
europepmc   +1 more source

Gendex--DEX Module for Constructing D-Optimal Treatment Designs

, 2001
Walter T. Fédérer, Nam‐Ky Nguyen, Sophonie Nshinyabakobeje   +2 more
openalex   +1 more source

Managing Technology Risk in R&D Project Planning: Optimal Timing and Parallelization of R&D Activities

, 2005
Pascale Crama, Bert deReyck, Zeger Degraeve, Roel Leus   +3 more
openalex   +1 more source